Presentations 2002
9th Conference on Retroviruses and opportunistic Infections in Seattle, February 2002
1. Interruption/Stopping Antiretroviral Therapy and the Risk of Clinical Diseases: Results from the EuroSIDA Study. JD Lundgren, S Vella, L Paddam, A Blaxhult, N Vetter, N Clumeck, G Panos, M Fisher, C Katlama, and AN Phillips.
(EuroSIDA 48)
2. Safe Interruption of Maintenance Therapy (MT) against Prior Infection with 4 Common HIV-Associated Opportunistic Pathogens during Highly Active Antiretroviral Therapy. O Kirk, P Reiss, C Uberti-Foppa, M Bickel, J Gerstoft, C Pradier, F Wit, B Ledergerber, JD Lundgren, and H Furrer for 7 European HIV cohorts.
(EuroSIDA 37)
3. Analysis of Virological Efficacy in Randomised Trials of Antiretroviral Regimens: Drawbacks of No HIV-RNA Measurements after Premature Interruption of Therapy. O Kirk, M Law, C Pedersen. RM Gulick, G Moyle, AN Phillips, and JD Lundgren.
(EuroSIDA Abstract G104e, Poster 551-T)
4. Distinguishable Lipid Profiles between PI and NNRTI Therapy May Carry Different Risk of CardiovascularDisease (CVD). F van Leth, N Friis-Møller, R Weber, A d'Arminio Monforte, O Kirk, R Thiebaut, L Morfeldt, C Pradier, G Calvo, M Law, G Bartsch, S De Wit, C Sabin, JD Lundgren, P Reiss for the D:A:D Study Group.
(DAD 34)
5. The Interim Analysis of a Phase IV Randomised, Open-Label, Multicentre Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg bid) vs. Saquinavir/Ritonavir (1000/100 mg bid) in Adult HIV-1 Infection: The MaxCmin1 Trial. A Castagna, UB Dragsted, J-P Chave, A Rieger, G Carosi, S van der Geest, H Nielsen, and JD Lundgren on behalf of the MaxCmin1 trial group.
(MaxCmin G1008e)
British HIV Association Conference, York, April 2002
1. Current status of patients starting HAART during 1996: descriptive analysis of EuroSIDA participants. Lucy Paddam, O Kirk, JM Gatell, P Reiss, F Antunes, AM Johnson, A Horban, C Pradier, B Ledergerber, AN Phillips, and JD Lundgren on behalf of The EuroSIDA Study Group.
(EuroSIDA)
The 14th International AIDS Conference, Barcelona, July 2002
1. Modelling Risk of Cardiovascular Events in HIV. M Law, N. Friis-Møller, R Weber, P Reiss, A d'Arminio Monforte, O Kirk, R Thiebaut, C Pradier, L Morfeldt, G Calvo, G Bartsch, S De Witt, C Sabin, JD Lundgren for the D:A:D Study Group.
(DAD WePeC6260)
2. Virological, immunological and clinical response to highly active antiretroviral therapy: the gender issue revisited. AL Moore, O Kirk, JD Lundgren, AN Phillips
(EuroSIDA B10508)
3. Week 48 data of a randomised trial to evaluate safety and efficacy of indinavir/ritonavir (800/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection. P Cahn, UB Dragsted, C Pedersen, B Peters, A Duran, N Obel, JM Gatell, C Leen, J v Lunzen, A Stoehr, J Lederman, and JD Lundgren on behalf of the MaxCmin1 trial group.
(MaxCmin WeOrB1265)
4. A randomised trial comparing HAART regimens of Nelfinavir/Nevirapine and Ritonavir/Saquinavir in PI and NNRTI naïve patients. O Kirk, JD Lundgren, C Pedersen, L Mathiesen, H Nielsen, T Katzenstein, N Obel, J Gerstoft.
(DAPIS TuOrB1188)
5. What is the prognostic value of baseline CD4 cell count and viral load six months after initiating potent antiretroviral therapy? ART Cohort Collaboration. JAC Sterne, S Grabar, A d’Arminio Monforte, M Rickenbach, F de Wolf, JD Lundgren, J Fusco, V Miller, F Raffi, F Dabis, RS Hogg, F Lampe, MJ Gill, B salzberger, M May, M Egger.
(ART Cohort C10680)
6. Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration. G Chene, M May, D Costagliola, A d’Arminio Monforte, C Junghans, F de Wolf, JD Lundgren, G Fusco, V Miller, C Leport, F Dabis, RS Hogg, AN Phillips, MH Gill, B Salzberger, JAC Sterne, M Egger.
(ART Cohort TuOrB1140)
7. Construction and validation of a prognostic model for progression to AIDS or death in drug-naïve patients starting potent antiretroviral therapy ART Cohort Collaboration. M May, JAC Sterne, D Costagliola, P Pezzotti, B Ledergerber, F de Wolf, JD Lundgren, AC Justice, V Miller, G Chene, F Cabid, RS Hogg, C Sabin, MJ Gill, B Salzberger, M Egger.
(ART Cohort TuPeB4668)
42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, December 2002
1. Final Analysis of a Randomised Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir versus Saquinavir/Ritonavir in Adult HIV-1 Infection: The MaxCmin1 Trial. J Gerstoft, UB Dragsted, P Cahn, A Castagna, A Duran, A Hill, C Pedersen, B Peters, P Vernazza, M Youle, and JD Lundgren on behalf of the MaxCmin1 trial group.
(MaxCmin ICAAC02-A-2853-ASM)
2. Abacavir, Didanosine and Stavudine versus Ritonavir, Saquinavir, Zidovudine and Lamivudine or Nelfinavir, Nevirapine, Zidovudine and Lamivudine in Antiretroviral Naïve HIV Patients. J Gerstoft, O Kirk, N Obel, H Nielsen, L Mathiesen, C Pedersen, J Lundgren.
3. The Evolution of HIV in Patients with Insufficient Viral Suppression during HAART. TB Kristiansen, AG Pedersen, J Eugen-Olsen, T Katzenstein, JD Lundgren.
6th Congress on Drug Therapy in HIV Infection, Glasgow, November 2002
1. Lipid profiles on therapy with PI. The D:A:D Study. C Pradier, C Sabin, N Friis-Møller, R Weber, P Reiss, A d'Arminio Monforte, O Kirk, R Thiebaut, E Fontas, L Morfeldt , G Calvo, M Law, G Bartsch, S De Witt, JD Lundgren for the DAD Study Group.
(DAD PL21.1)
2. Virological rebound after suppression on HAART: result from the EuroSIDA study. A Mocroft, A Phillips, P Reiss, B Clotet, B Ledergerber, J Gatell, C Katlama, S Vella, N Clumeck, JD Lundgren
(EuroSIDA PL5.4)
3. The interim analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of Lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid) in adult HIV-1 infection: The MaxCmin2 trial. UB Dragsted, J Gerstoft, M Youle, A Duran, DT Jayaweera, A Rieger, JN Bruun, A Castagna, S Walmsley, Z Fox, A Hill, and JD Lundgren for the MaxCmin2 trial group.
(MaxCmin2 PL14.5)
4. Final Safety and Efficacy Analysis of a Randomised Trial Evaluating Indinavir/Ritonavir versus Saquinavir/Ritonavir in Adult HIV-1 Infection: The MaxCmin1 Trial. J Gerstoft, U Bak Dragsted, P Cahn, A Castagna, A Duran, A Hill, C Pedersen, B Peters, P Vernazza, M Youle, and JD Lundgren on behalf of the MaxCmin1 trial group.
(MaxCmin P29)
4th European Conference on the Methods and Results of Social and Behavioural Research on AIDS, September 2002, Vilnius.
1. The EuroSIDA Study 1994-2002. O Kirk, on behalf of the EuroSIDA study Group.
Updated: 13 Dec 2005